The NYU RNAi Core is pleased to announce a funding cycle for stem-cell related screening projects. The NYU RNAi Core provides an integrated, state-of-the-art RNA interference (RNAi) based high-throughput screening (HTS) facility at the NYU Langone
Medical Center. The core offers siRNA/dsRNA/miRNA screening libraries and cutting edge automation equipment for the cross-species functional characterization of whole genomes in a systematic, comprehensive, and cost effective manner. In addition, the facility provides logistic, technical, and bioinformatic support in order to assist screeners in performing and interpreting their genome scale RNAi screens. We remain strongly committed to making the NYU RNAi Core fully accessible to the entire NY academic community and to facilitate inter-disciplinary and multi-institutional collaborations.
Eligibility
This funding opportunity is open to Principal Investigators in New York State.
Applications must be for stem-cell related projects.
Funding details
The cell-based assay must be first developed in the PI's lab. Award recipients will receive an optimization subsidy (up to $3000) that would be specifically applied to training, consultation with core staff, equipment usage, and some reagents associated with assay optimization for HTS RNAi screening. The purpose of the subsidy is to defray the cost of NYU RNAi Core equipment/resources to develop an optimized, robust
384-well assay in preparation for screening at the Core.
If assay optimization is deemed successful as judged by NYU RNAi Core staff, an additional screening subsidy of up to $12,000 will be available to be applied to screening fees, equipment usage, and reagents associated with the primary screen.
Application process
All applications will be considered confidential, and should be emailed to applicationrnai@nyumc.org
Review criteria will include feasibility of the cell-based assay, scientific merit, and budget justifications. Approval and amount of screening subsidy will be determined by the innovation, likelihood of success, and budgetary requirements.

Terms and Conditions of Awards
All screeners must sign the RNAi Core Acknowledgment and Data Sharing Agreements.
The amount and approval of the additional subsidy for screening are contingent upon successful optimization and budgetary requirements as judged by NYU RNAi Core staff.
The subsidy for screening fees is applicable ONLY to those screens that are completed. If the screen is aborted by the initiating PI/lab during test plate usage or the pilot screen, the subsidy will no longer apply, and the screener will be charged for normal facility usage.
Contact information
For additional information, please contact:
Chi Yun, PhD., Director, NYU RNAi Core: chi.yun@nyumc.org

Funding Application Form for NYU RNAi Core Screening Projects
After familiarizing yourself with our policy, screening fees, and data sharing agreement, please submit:
* This form
* CV or resume
* Copy of relevant review or publication
PLEASE SUBMIT THESE DOCUMENTS ALONG WITH THIS FORM TO rnai@nyumc.org
Contact information
Name:
Email:
Phone:
PI:
Institution:
Applicant's position in lab:
Screening information
Which library are you planning to screen? (Screening fees are based on libraries screened in triplicate).
Human miRNA mimic
Human miRNA inhibitor
Human whole genome
Mouse miRNA mimic
Mouse miRNA inhibitor
Mouse whole genome
Drosophila whole genome
Drosophila subset (describe below)
_______________________________________________
Plate type:
Black clear bottom for visual and fluorescence assays (Corning 3712)
White bottom for luciferase assays (Corning 3570)

Title and description of proposed screen including background
________________________________________________________________
______
________________________________________________________________
_______
Please describe how this is a stem cell related project
________________________________________________________________
________________________________________________________________
________________
Please describe your preliminary results or assay development, including behavior of positive and negative siRNA or dsRNA controls, if available. If you do not have such controls, please explain how you plan to assess your assay robustness or interpret your screening data.
________________________________________________________________
________